Home / Biopharma / Short Call on Analysts Review: Bristol-Myers Squibb (NYSE:BMY), Exact Sciences (NASDAQ:EXAS)

Short Call on Analysts Review: Bristol-Myers Squibb (NYSE:BMY), Exact Sciences (NASDAQ:EXAS)

Bristol-Myers Squibb Company (NYSE:BMY) [Trend Analysis] moved down reacts as active mover, shares a loss -0.82% to traded at $56.51 and the percentage gap between open changing to regular change was -0.11%.

Finally, analysts shed their light over the BMY price targets; maintaining price high target of 100.00 while at average the price target was 63.92 in contrast with the current price of 56.51. The price targets are usually acts as the boosters or blasters in the performance of stock. A higher price target would definitely provide confidence to investors during the trading action, consideration given by Wall Street Journal.

So does the rankings given by analysts; let us highlight rankings table and we had 10 analyst recommending BUY ratings for current month and for previous month 11 stands on similar situation; while 12 for the current month as compared to 12 analysts recommending for HOLD from the pool for previous month. While 1 stands at overweight and 1 analyst gave Underweight and 1 out of pool consider it as Sell for current month. For the overall, consensus ratings were for Overweight.

The firm’s current ratio calculated as 1.50 for the most recent quarter. The firm past twelve months price to sales ratio was 5.11 and price to cash ratio remained 16.99. As far as the returns are concern, the return on equity was recorded as 22.70% and return on investment was 4.60% while its return on asset stayed at 10.30%. The firm has total debt to equity ratio measured as 0.44.

Exact Sciences Corporation (NASDAQ:EXAS) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -3.92% to $15.19.

Fundamentalist can give brighter side of a picture but an analyst can glow the darker parts stored in any investment. Let us view how analysts have ranked EXAS in recent few months. In ratings table the EXAS given BUY ratings by 5 analyst in current phase and 1 analyst suggest it as overweight security. The 0 number of analyst/s have SELL recommendation for current month on EXAS. While 6 number of analysts gave ratings for HOLD in current. As per remarks given by WSJ, overall consensus pool recommend it as Overweight security.

The stock was assessed in terms of profitability as current quarter EPS estimate trends showed $-0.41 at current month while compared with $-0.41 in a month ago. The stock next year first quarter current estimate trend for EPS was for $-0.40 and on annual basis FY 2016 estimate trends at current was for $-1.71 as compared to one month ago of $-1.71, and for next year per share earnings estimates have $-1.45.

The share price of EXAS attracts active investors, as stock price of week volatility recorded 5.35%. The stock is going forward to its 52-week low with 225.27% and lagging behind from its 52-week high price with -33.38%.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Check Also

Endo International (NASDAQ:ENDP)- Concerns Wondering Stocks At New Rating: ZIOPHARM Oncology (NASDAQ:ZIOP)

Endo International plc (NASDAQ:ENDP) [Trend Analysis] try to make new thrust in street and making …

Leave a Reply

Your email address will not be published. Required fields are marked *